Peer-reviewed veterinary case report
Antibody changes in dogs treated for leishmaniasis infection
By Todolí, Felicitat et al.·Published in The American journal of tropical medicine and hygiene·2010·Unitat de Farmacologia Veterinà, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Dynamics and predictive potential of antibodies against insect-derived recombinant Leishmania infantum proteins during chemotherapy of naturally infected dogs.
- Species:
- dog
Plain-English summary
A group of 36 dogs with leishmaniasis (a disease caused by a parasite) was treated to see how their bodies responded to specific proteins from the parasite. Researchers found that the levels of certain antibodies in the dogs' blood dropped significantly earlier in dogs that recovered compared to those that remained sick after a year of treatment. This suggests that monitoring these antibody levels could help predict which dogs are likely to get better and stay healthy after treatment.
People also search for: dog leishmaniasis treatment · canine leishmaniasis recovery signs · leishmaniasis antibody testing in dogs
Abstract
A predictive marker for the success treatment of canine leishmaniasis is required for the application of a more rational therapy protocol, which must improve the probability of cure and reduce Leishmania resistance to drugs. We investigated the dynamics and predictive value of antibodies against insect-derived recombinant L. infantum proteins rKMPII and rTRYP by using an enzyme-linked immunosorbent assay with retrospective serum samples from 36 dogs during treatment of canine leishmaniasis. In the entire group of dogs, concentrations of antibodies against rKMPII and rTRYP significantly decreased earlier than concentrations of antibodies against crude total Leishmania antigen (one versus six months), which suggested that the dynamics of antibodies against recombinant proteins may be useful for assessing clinical improvement after treatment. Interestingly, decreases in antibody concentrations against rKMPII occurred earlier in disease-free dogs than in dogs that remain clinically ill one year after beginning of treatment, which suggested that these antibodies may be useful for predicting disease-free survival one year after the beginning of therapy against canine leishmaniasis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20439957/